Crystalline forms of a FGFR inhibitor and processes for preparing the same

US11472801B2 · kind B2 · utility

Assignee

• Incyte Corporation · US

Inventors

• Yongchun Pan · Wilmington, US
• Chongsheng Eric Shi · Wilmington, US
• Ming Tao · Masontown, US
• Wayne Han · West Chester, US
• Michael Xia · Wilmington, US
• Dengjin Wang · Levittown, US
• Zhongjiang Jia · Kennett Square, US
• Jiacheng Zhou · Shanghai, CN
• Qun Li · Beijing, CN

Key dates

• Filing date: Feb 6, 2020
• Grant date: Oct 18, 2022
• Expiry date: Feb 6, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07B2200/13
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present disclosure relates to solid forms of N-{[2′-(2,6-difluoro-3,5-dimethoxyphenyl)-3′-oxo-2′,3′-dihydro-1′H-spiro[cyclopropane-1,4′-[2,7]naphthyridin]-6′-yl]methyl}acrylamide, methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of the FGFR-associated or mediated diseases such as cancer.